skip to main content

News Archive

Date: 02/02/2023
When noninvasive sound waves break apart tumors, they trigger an immune response in mice. By breaking down the cell wall “cloak,” the treatment exposes cancer cell markers that had previously been hidden from the body’s defenses, researchers at the University of Michigan have shown. The technique developed at Michigan, known as histotripsy, offers a two-prong approach to attacking cancers: the physical destruction of tumors via sound waves and the kickstarting of the body’s immune response. The research shows the potential for this to become a treatment option for patients without the harmful side effects of radiation and chemotherapy.
Date: 02/01/2023
Five University of Michigan Rogel Cancer Center members were elected as 2022 fellows of the American Association for the Advancement of Science. They are among 17 University of Michigan faculty and staff members elected this year.
Date: 02/01/2023
Patients whose brain tumors have a mutated enzyme called IDH1 typically live longer than those without the mutation. But even as these tumors are initially less aggressive, they always come back. A key reason: The tumors are resistant to radiation treatment and are invasive.
Date: 01/17/2023
Immunotherapy has been a major advancement in cancer therapy, but it is not effective for all patients. In some instances, it can even cause tumors to “hyperprogress.” Researchers from the Rogel Cancer Center have found a mechanism for why a subset of patients’ tumors grow, rather than shrink, when faced with immunotherapy.
Date: 01/12/2023
By capturing and amplifying tiny sound waves created when X-rays heat tissues in the body, medical professionals can map the radiation dose within the body, giving them new data to guide treatments in real time. It’s a first-of-its-kind view of an interaction doctors have previously been unable to "see."
Date: 01/10/2023
Anao Zhang, Ph.D., LCSW, ACSW, ACBT is principal investigator on a new project funded with a $250,000 Eugene Washington PCORI Engagement Award, an initiative of the Patient-Centered Outcomes Research Institute, or PCORI. The research team will build out existing research infrastructure in patient-centered outcomes to enhance participation from AYA cancer survivors who identify as BIPOC or sexual and gender minorities.
Date: 12/28/2022
Most colorectal cancers are insensitive to immune therapies. This research indicates one of the mechanisms leading to this resistance is likely the high level of ammonia that accumulates in the microenvironment.
Date: 12/26/2022
Undergoing emergency surgery was associated with a higher rate of complications, including death. Out of close to 5,000 patients who underwent any type of surgery for colorectal cancer, 23% had emergency surgery -- but those patients made up 63% of the deaths.
Date: 12/09/2022
Researchers at the University of Michigan Rogel Cancer Center and School of Dentistry found that certain drugs can change the fundamental makeup of cancer stem cells in mouse models of mucoepidermoid carcinoma – a lethal form of salivary gland cancer that currently has no treatment options.
Date: 12/07/2022
Rogel Cancer Center faculty and trainees will lead more than two dozen presentations, posters and moderated sessions at the American Society of Hematology annual meeting. This year’s meeting will be held in-person and virtually.